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Abstract
The expression of gangliosides is often associated with cancer progression. Sialyltransferases have received much attention
in terms of their relationship with cancer because they modulate the expression of gangliosides. We previously
demonstrated that GD1a production was high in castration-resistant prostate cancer cell lines, PC3 and DU145, mainly due
to their high expression of b-galactoside a2,3-sialyltransferase (ST3Gal) II (not ST3Gal I), and the expression of both ST3Gals
was regulated by NF-kB, mainly by RelB. We herein demonstrate that GD1a was produced in abundance in cancerous tissue
samples from human patients with hormone-sensitive prostate cancers as well as castration-resistant prostate cancers. The
expression of ST3Gal II was constitutively activated in castration-resistant prostate cancer cell lines, PC3 and DU145, because
of the hypomethylation of CpG island in its promoter. However, in androgen-depleted LNCap cells, a hormone-sensitive
prostate cancer cell line, the expression of ST3Gal II was silenced because of the hypermethylation of the promoter region.
The expression of ST3Gal II in LNCap cells increased with testosterone treatment because of the demethylation of the CpG
sites. This testosterone-dependent ST3Gal II expression was suppressed by RelB siRNA, indicating that RelB activated ST3Gal
II transcription in the testosterone-induced demethylated promoter. Therefore, in hormone-sensitive prostate cancers, the
production of GD1a may be regulated by androgen. This is the first report indicating that the expression of a
sialyltransferase is transcriptionally regulated by androgen-dependent demethylation of the CpG sites in its gene promoter.
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Introduction
Many cancer cells have aberrant sialylated glycans on their
surface. These aberrant molecules may be involved in cancer
progression [1–3], but sialylated glycans also play many roles in
healthy organisms and non-cancer cells, including embryogenesis,
regulation of the immune response and virus binding that leads to
infections [4,5]. Sialylated glycans are synthesized by sialyltrans-
ferases, which add sialic acids to the oligosaccharide chains of
glycoproteins and glycosphingolipids (GSLs) [5]. To date, 20
sialyltransferase genes have been cloned, and the respective
enzymes have been grouped into four families according to the
carbohydrate linkages they catalyze: b-galactoside a2,3-sialyl-
transferases (ST3Gal I–VI), b-galactoside a2,6-sialyltransferases
(ST6Gal I and II), GalNAc a2,6-sialyltransferases (ST6GalNAc I–
VI), and a2,8-sialyltransferases (ST8Sia I–VI) [6]. During
neoplastic transformation and cancer progression, the activity of
sialyltransferases is often altered, and consequently, cancer cells
have more heavily sialylated glycans on their surface than non-
cancer cells [1,2,7].
GSLs that contain sialic acids are known as gangliosides and are
expressed at high levels in various cancer cells [3]. The
gangliosides present on cancer cells are used as biomarkers or
treatment targets, and the enriched gangliosides differ between
cancer cell types [8–10]. We have focused on GD1a synthesis in
cancer cells because GD1a has several biological actions that
promote cancer progression. For example, highly metastatic
cancer cells have abundant GD1a, and GD1a is involved in
cancer cell adhesion to endothelial cells during metastasis [11].
The GD1a shed by tumor cells in the tumor microenvironment
promotes angiogenesis and enhances growth factor signaling by
increasing the dimerization of growth factor receptors [12–15].
Therefore, GD1a may be involved in cancer cell proliferation and
metastasis. Furthermore, this ganglioside is a receptor for the
Sendai virus [16], and inactivated Sendai virus particles
[hemagglutinating virus of Japan envelope (HVJ-E)] induce
apoptosis in several human cancer cells with enriched GD1a on
their surface [17]. Therefore, GD1a may be an attractive molecule
from the viewpoint of cancer therapy.
GD1a has been reported to be abundantly produced in
castration-resistant prostate cancer cells [17–20], and we previ-
ously demonstrated that castration-resistant prostate cancer cells
were effectively eradicated by HVJ-E [17]. GD1a is synthesized
from GM1 by ST3Gal I and II. The Km value of ST3Gal II for
GM1 is smaller than that of ST3Gal I; thus, ST3Gal II
preferentially contributes to GD1a synthesis [6,21–24]. We
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castration-resistant prostate cancer cells is correlated with the high
levels of ST3Gal II expression [20] and that ST3Gal II expression
is regulated by NF-kB, mainly by RelB, in castration-resistant
prostate cancer cells [20]. Although the RelB levels were similar in
a hormone-sensitive prostate cancer cell line (LNCap) and
castration-resistant prostate cancer cells, and although ST3Gal I
was expressed in LNCap cells [20], the expression of ST3Gal II
was silenced in LNCap cells, and GD1a was much less abundant
in the LNCap cells [17,20].
There has so far been no published analysis of the ganglioside
levels in cancerous tissue samples from human patients with
prostate cancer; however, an endogenous immune response to
GD1a was observed in patients with hormone-sensitive prostate
cancer, but not in healthy controls [19], thus suggesting that GD1a
is abundantly produced in hormone-sensitive prostate cancers.
Prostate cancer exhibits androgen-dependent growth and progres-
sion [25]; therefore, androgens may also regulate the GD1a
production that is related to cancer progression. However, there
have also been no published studies that have examined the
hormonal control of sialylated glycan synthesis.
The aim of this study was to determine whether GD1a is
produced in abundance in hormone-sensitive prostate cancers in
patients and to analyze the transcriptional control of sialyltrans-
ferases, especially ST3Gal II, required for the synthesis of GD1a in
hormone-sensitive prostate cancers.
Materials and Methods
Ethics statement
Written informed consent was obtained from all patients for the
use of their tissue specimens, and the use of such specimens was
approved by the Osaka University Hospital Institutional Review
Board (Osaka, Japan).
Cell culture
Castration-resistant human prostate cancer cell lines, PC3 and
DU145, and a hormone-sensitive human prostate cancer cell line,
LNCap clone FGC, were purchased from the American Type
Culture Collection (Rockville, MD). A normal human prostatic
epithelial cell, PNT2, was purchased from the European
Collection of Animal Cell Cultures (Porton Down, UK). PC3
cells were maintained in Dulbecco’s modified Eagle F12 medium
(Nacalai Tesque, Kyoto, Japan), and DU145, LNCap, and PNT2
cells were maintained in RPMI 1640 medium (Nacalai Tesque,
Kyoto, Japan). All media were supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml
streptomycin. The cells were incubated at 37uC in a humidified
atmosphere of 95% air and 5% CO2.
Reagents and antibodies
Trichostatin A (TSA) and 5-aza-29-deoxycytidine (5-azadC)
were purchased from Wako Pure Chemical Industries (Osaka,
Japan). Testosterone was purchased from Tokyo Chemical
Industry (Tokyo, Japan). Bicalutamide was purchased from Enzo
Life Sciences (Plymouth Meeting, PA). Restriction enzymes, MspI
and HpaII, were purchased from New England Biolabs (Ipswich,
MA). Anti-human RelB (C1E4) was purchased from Cell Signaling
(Danvers, MA). Anti-human b-actin (AC-15) was purchased from
Abcam (Cambridge, UK).
Real-time quantitative RT-PCR
Total RNA was isolated using an RNeasy RNA isolation kit
(Qiagen, Valencia, CA). The cDNA was synthesized using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA). Real-time quantitative PCR was performed with
an Applied Biosystems 7900 HT Fast Real-Time PCR system
under the following conditions: 95uC for 10 min followed by 40
cycles of 95uC for 15 s and 60uC for 1 min. Mixtures of probes
and primer pairs specific for human ST3Gal I (Hs00161688_m1),
ST3Gal II (Hs00199480_m1), ST3Gal VI (Hs00196086_m1),
RelB (Hs00232399_m1), and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) (Hs99999905_m1) were purchased from
Applied Biosystems. The relative expression levels were calculated
from a standard curve obtained using log dilutions of cDNA
containing the gene of interest, and values were normalized to
GAPDH, an internal control.
Evaluation using a reporter gene
Genes were transfected into cells along with a luciferase reporter
construct driven by a NF-kB binding site, RelA, and RelB (NF-kB
luciferase reporter gene; BD Bioscience Clontech, Palo Alto, CA),
using the Fugene HD reagent (Roche, Basel, Switzerland). The
luciferase activity was measured with the dual-luciferase assay
system (Promega, Madison, WI).
Western blot analysis
The cells were harvested and lysed with RIPA lysis buffer.
Protein samples were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis. The separated proteins were
transferred onto polyvinylidene fluoride membranes, then the
membranes were blocked with 5% skim milk and incubated
overnight at 4uC with anti-RelB (1:500) or anti-b-actin (1:2000)
antibodies. The membranes were washed and labeled with a
1:2000 dilution of horseradish peroxidase–conjugated secondary
antibody (GE Healthcare, Buckinghamshire, UK) at room
temperature for approximately 1 hour. Detection by chemilumi-
nescence was performed according to the ECL user’s guide
(Amersham, Buckinghamshire, UK). Images were captured with
ImageQuant LAS 4000mini (GE Healthcare, Buckinghamshire,
UK), and quantification of Western blot signals was performed by
densitometry with ImageQuant TL software (GE Healthcare,
Buckinghamshire, UK).
RNA interference experiments
The following double-strand stealth small interfering RNA
(siRNA) oligonucleotides and scrambled RNA were purchased
from Invitrogen (Tokyo, Japan): siRNA oligonucleotides against
RelB were (sense) 59-UCUUCAGGGACCCAGCGUUGUAG-
GG-39 and (antisense) 59-CCCUACAACGCUGGGUCCCUGA-
AGA-39. Transfections were performed with lipofectamine
RNAiMAX (Invitrogen, Tokyo, Japan), according to the manu-
facturer’s instructions.
Methylation-specific PCR (MSP) analysis
DNA methylation was examined at the CpG islands by a MSP
analysis as previously reported [26]. For the MSP analysis,
genomic DNA was extracted from cells and purified using the
QIAamp DNA kit (Qiagen, Valencia, CA). Genomic DNA was
subjected to bisulfite conversion using an EZ DNA Methylation
Kit (Zymo Research, Irvine, CA). Based on the sequence of the
ST3Gal II p1 promoter and ST3Gal I p1 promoter, methylated-
specific primers and unmethylated-specific primers were designed
using the Methyl Primer Express Software program version 1.0
(Applied Biosystems, Foster City, CA). The ST3Gal II-methylat-
ed-specific primers were sense, 59-TAGGGCGTAGCGGTTT-
TATC-39, antisense, 59-ACTAACCGAAAACGCCTCTC-39,
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GGTTAGGGTGTAGTGGTTTTATT-39, and antisense, 59-
CACACTAACCAAAAACACCTCTC-39. The ST3Gal II 59-
untranslated region from 2659 to 2495 was chosen for the MSP
analysis. The ST3Gal I-methylated-specific primers were sense,
59-TAGGGTCGGTCGTAGTGTTC-39, antisense, 59-ACCGA-
TCCCCTACTAACGAC-39, and the ST3Gal I-unmethylated-
specific primers were sense, 59-TTAGGGTTGGTTGTAGTG-
TTT-39, and antisense, 59-AACCAATCCCCTACTAACAAC-
39. The ST3Gal I 59-untranslated region from 2697 to 2535 was
chosen for the MSP analysis. The glutathione S-transferase-p gene
(GSTP1) -methylated-specific primers were sense, 59-AGTT-
GCGCGGCGATTTC-39, antisense, 59-GCCCCAATACTAAA-
TCACGACG-39, and the GSTP1-unmethylated-specific primers
were sense, 59-GATGTTTGGGGTGTAGTGGTTGTT-39, and
antisense, 59-CCACCCCAATACTAAATCACAACA-39, as de-
scribed previously [27]. Purified genomic DNA treated with
sodium bisulfite was amplified by PCR as follows: 2 min at 95uC
for denaturation, 35 cycles of amplification (95uC for 30 s, 56uC
for 30 s, and 72uC for 30 s). Human genomic DNA or
enzymatically methylated human genomic DNA (Chemicon
International, Temecula, CA) was bisulfite-converted and used
as a positive control for the unmethylated or methylated genes.
The absence of a DNA template served as a negative control. The
products were analyzed in 2% agarose gels stained with ethidium
bromide.
Isolation of acidic GSLs from prostate cancer tissues
Patients diagnosed with prostate cancer had undergone prostate
biopsy or resection of tumors at Osaka University Hospital (Osaka,
Japan). Primary cancerous tissue samples were frozen in liquid
nitrogen and stored at 280uC until use. The majority of the
experimental procedures have been reported previously [28]. In
brief, the samples were homogenized in chloroform/methanol
(2:1, v/v), and incubated at room temperature for 2 h with 30 s of
sonication every 30 min. Methanol was then added to the samples,
which were centrifuged at 18006g for 15 min. The pellets were
homogenized in chloroform/methanol/water (1:2:0.8, v/v/v),
incubated at room temperature for 2 h, and then centrifuged at
18006g for 15 min. Both extracts were combined and evaporated
to dryness in a vacuum concentrator. The residue was dissolved in
chloroform/methanol/water (30:60:8) and fractionated by
DEAE–Sephadex A25 column chromatography to separate
neutral GSLs from acidic GSLs.
Analysis of acidic GSLs
The structures of the acidic GSLs were analyzed by enzymatic
release of carbohydrate moieties, fluorescent labeling with
aminopyridine, and two-dimensional mapping followed by mass
spectrometry. The majority of experimental procedures have been
reported previously [28]. In brief, the acidic GSLs were extracted
from primary cancer tissue samples or cultured cancer cells and
digested with recombinant endoglycoceramidase II from Rhodo-
coccus sp. (Takara Bio Inc., Shiga, Japan). The released
oligosaccharides were labeled with 2-aminopyridine (2-AP) and
separated on a Shimadzu LC-20A HPLC system (Shimadzu
Corporation, Kyoto, Japan) equipped with a Waters 2475
fluorescence detector. Normal-phase HPLC was performed on a
TSK gel Amide-80 column (0.2625 cm, Tosoh, Tokyo, Japan).
The molecular size of each pyridylaminated (PA)-oligosaccharide
is given in glucose units (Gu) based on the elution times of PA-
isomaltooligosaccharides. Reversed-phase HPLC was performed
on a TSK gel ODS-80Ts column (0.2615 cm, Tosoh). The
retention time of each PA-oligosaccharide is given in glucose units
based on the elution times of the PA-isomaltooligosaccharides.
Therefore, the behaviors of a given compound in these two
columns provide a unique set of Gu (amide) and Gu (ODS) values,
which correspond to coordinates on a 2-D map. PA-oligosaccha-
rides were analyzed by LC/ESI MS/MS. Standard PA-oligosac-
charides, PA-GM1 and PA-GD1a, were purchased from Takara
Bio, and PA-LST-a and PA-SPG were isolated as in our previous
study [28].
Statistical analyses
The results are reported as the means 6 standard error (S.E.).
The two-tailed unpaired Student’s t-test was used to determine the
statistical significance of the differences between two groups.
Probability values of P,0.05 were considered to be statistically
significant. The statistical analysis was performed using the
StatView 5.0 software program (SAS Institute, Cary, NC).
Results
Analyses of gangliosides in cancerous tissue samples
from patients with prostate cancer
We previously demonstrated that GD1a was abundant in
castration-resistant prostate cancer cell lines (including PC3 and
DU145), while it was barely detectable in a hormone-sensitive
prostate cancer cell line (LNCap) and a normal prostate epithelial
cell line (PNT2) [17]. We examined the levels of gangliosides in
samples of cancerous tissue from eight patients with prostate
cancer, including six patients with advanced hormone-sensitive
prostate cancer and two patients with castration-resistant prostate
cancer (Table 1). The acidic GSLs extracted from cancerous tissue
samples from these patients were examined using HPLC (Fig. 1).
Both GM3 and GD3 are common gangliosides expressed in both
prostate cancer cells and normal prostate epithelial cells [18,19].
GD1a was produced in the cancerous tissue samples from both the
patients with hormone-sensitive prostate cancers and those with
castration-resistant prostate cancers (Fig. 1A, 1B). In all of the
patient’ samples (hormone-sensitive and castration-resistant), the
mean percentage of total acidic GSLs with GD1a was 8.1%, and
no statistically significant difference was seen compared with the
value from castration-resistant prostate cancer cell lines (PC3 and
DU145) (Fig. 1C).
Androgen-dependent regulation of ST3Gal II in LNCap
cells
The synthesis of GD1a is mainly regulated by ST3Gal II, and
the expression of ST3Gal II is regulated by NF-kB, mainly by
Table 1. Patient characteristics.
Patient Site HS/CR PSA Gleason sum
1 Prostate/Bone metastasis HS 706 8
2 Prostate HS 914 9
3 Prostate HS 2800 9
4 Prostate HS 3.1 9
5 Prostate HS 639 9
6 Prostate HS 2296 9
7 Prostate CR 36 -
8 Prostate CR 6.2 -
HS, Hormone-sensitive; CR, Castration-resistant.
doi:10.1371/journal.pone.0031234.t001
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GSLs from the cancerous tissue samples from eight patients with prostate cancer, including six patients with advanced hormone-sensitive prostate
cancer and two patients with castration-resistant prostate cancer were separated by the molecular size of the oligosaccharides using normal-phase
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amounts of nuclear RelB were similar in hormone-sensitive
LNCap cells and castration-resistant PC3 and DU145 cells [20],
but the expression of ST3Gal II was lower in the LNCap cells than
in the PC3 and DU145 cells [20].
The LNCap cell culture medium is routinely supplemented with
10% fetal bovine serum (FBS). A recent report showed that media
supplemented with 10% FBS contains only castrate levels of
testosterone [29]; in contrast, hormone-sensitive prostate cancers
of untreated patients usually grow in an environment containing
testosterone in vivo. To analyze the transcriptional control of
ST3Gal II in hormone-sensitive prostate cancers, we examined
whether the expression of ST3Gal II was controlled by
testosterone in LNCap cells. LNCap cells were treated with
testosterone (0–1000 nM), and were incubated for 120 h. The
quantitative real-time PCR analyses showed that the expression of
ST3Gal II was higher in LNCap cells treated with testosterone
than in the LNCap cells that were not (Fig. 2A). Furthermore, the
induction of ST3Gal II after testosterone treatment was sup-
pressed by an anti-androgen, bicalutamide, in LNCap cells
(Fig. 2B). To ensure that there were no androgens present in the
media, LNCap cells were incubated in charcoal-stripped serum for
48 h. The basal level of ST3Gal II was not significantly different
between the 10% FBS- and charcoal stripped serum-supplement-
ed LNCap cells (Fig. 2C). The LNCap cells were subsequently
treated with 100 nM testosterone, and the time-course of
expression following testosterone treatment was evaluated. The
expression of ST3Gal II was increased 48 h after testosterone
treatment, and remained elevated for more than 120 h in the
LNCap cells (Fig. 2C). To evaluate the NF-kB activity after
testosterone treatment, LNCap cells were transfected with an NF-
kB luciferase reporter construct and incubated for 120 h with or
without testosterone. The NF-kB activity was not significantly
different in the testosterone-treated LNCap cells compared to the
cells cultured without testosterone (Figure S1). In PC3 and PNT2
cells, no significant increase in the expression of ST3Gal II was
detected regardless of whether the cells cultured with or without
testosterone (Fig. 2A). The expression of ST3Gal II did not
increase after testosterone treatment in the PC3 cells at any time
point up to 120 h (Figure S2). Based on these findings, we
hypothesized that the media with castrate levels of testosterone led
to the epigenetic silencing of ST3Gal, a gene required for the
synthesis of GD1a, in LNCap cells.
Epigenetic regulation of ST3Gal II in LNCap cells
Next, we examined whether ST3Gal II was epigenetically
regulated in LNCap cells. The LNCap cells were treated with a
DNA methyltransferase inhibitor, 5-azadC, and incubated for
120 h (Fig. 3A). The quantitative real-time PCR analyses showed
that the expression of ST3Gal II was up-regulated after 5-azadC
treatment. Following this experiment, the LNCap cells were
treated with a histone deacetylase inhibitor, TSA, and incubated
for 48 h (Fig. 3B). The quantitative real-time PCR analyses
showed that the expression of ST3Gal II was up-regulated after
TSA treatment. These results suggest that epigenetic regulation,
including DNA methylation and histone modifications, may be
involved in the repression of the ST3Gal II gene in LNCap cells.
In further experiments, we focused on DNA methylation at the
CpG island in the ST3Gal II promoter.
Control of DNA methylation at the CpG island in the
ST3Gal II gene promoter in prostate cancer cells
The gene for human ST3Gal II has been cloned, and the p1
promoter is reportedly necessary for active transcription of this
gene in prostate cancer cells [30]. The ST3Gal II promoter
sequences are publically available, and we identified a CpG island
in the ST3Gal II p1 promoter using the Methyl Primer Express
Software program, version 1.0 (Applied Biosystems, Foster City,
CA) (Fig. 4A). We examined the methylation at the CpG in the
ST3Gal II promoter using the MSP analysis. Genomic DNA was
isolated from LNCap cells treated with or without 5-azadC for
120 h, that were then treated with sodium bisulfite, and the DNA
was amplified with primers specific for the unmethylated or the
methylated ST3Gal II promoter (Fig. 4B). In LNCap cells, the
CpG island in the ST3Gal II promoter, which was originally
hypermethylated, was demethylated by 5-azadC treatment. Next,
we examined the effect of testosterone on the methylation at the
CpG in the ST3Gal II promoter in LNCap cells using a MSP
analysis (Fig. 4C). In the PC3 and DU145 cells, the CpG island of
the ST3Gal II promoter was constitutively hypomethylated. In the
LNCap cells, the CpG island of the ST3Gal II promoter was
hypermethylated in the absence of testosterone and demethylated
in the presence of testosterone. Furthermore, the demethylation at
the CpG island in the ST3Gal II promoter after testosterone
treatment was suppressed by an anti-androgen, bicalutamide, in
LNCap cells (Fig. 4D).
We also examined whether global DNA demethylation is under
androgen-dependent control in LNCap cells. We examined the
overall restriction patterns of MspI- or HpaII-digested genomic
DNA. These enzymes are isoschizomers that recognize the target
sequence 59-CCGG-39, but the activity of HpaII is inhibited by
methylation of the inner cytosine of this sequence. The genomic
DNA isolated form LNCap cells treated with or without
testosterone was digested using MspIo rHpaII (Figure S3A).
Testosterone treatment did not greatly affect the digestion pattern
of HpaII-treated genomic DNA from LNCap cells, indicating that
global DNA demethylation in LNCap cells was not under
androgen-dependent control. We then examined the CpG island
of GSTP1, which is reported to be hypermethylated during
prostate carcinogenesis and also in LNCap cells [27]. Based on the
MSP analysis, testosterone treatment did not affect the methyla-
tion of GSTP1 in LNCap cells (Figure S3B). Thus, the androgen-
dependent control of DNA demethylation may be induced
preferentially at the CpG island in the ST3Gal II gene promoter
in LNCap cells.
Androgen-dependent and epigenetic regulation of
ST3Gal I in LNCap cells
Although GD1a is synthesized from GM1 mainly by ST3Gal II,
ST3Gal I may also contribute to the synthesis of GD1a [6,21–24].
We previously reported that ST3Gal I was expressed in LNCap
cells, while the expression of ST3Gal II was silenced [20].
HPLC. Samples from one patient (designated Case 1) were taken from both the prostate and bone metastases for evaluation. (B) The acidic GSLs in
the primary cancerous tissue samples were separated by the molecular size of the oligosaccharides using HPLC. The quantity of GD1a is presented as
a percentage of the total acidic GSLs with GD1a. (C) The acidic GSLs in cultured prostate cancer cells were separated by the molecular size of the
oligosaccharides using HPLC. The assay was done in triplicate, and the means 6 S.E. GD1a levels are shown as the ratio to the total acidic GSLs in the
cell lines. The mean 6 S.E. GD1a level was also presented as the ratio to the total acidic GSLs in the patients’ samples (HS+CR) indicated in Figure 1B.
(HS, hormone-sensitive; CR, castration-resistant; F, free glycan).
doi:10.1371/journal.pone.0031234.g001
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different from that of ST3Gal II. We thereafter examined whether
the expression of ST3Gal I, like ST3Gal II, was controlled by
testosterone in LNCap cells. In this experiment, the LNCap cells
were treated with testosterone and incubated for 120 h. The
quantitative real-time PCR analyses showed that testosterone
treatment resulted in increased expression of ST3Gal I in LNCap
cells (Fig. 5A), although the expression of ST3Gal VI, the
sialyltransferase required for the synthesis of sialyl paragloboside,
was not induced by testosterone treatment (Figure S4). Further-
more, the testosterone-mediated induction of ST3Gal I in LNCap
cells was suppressed by bicalutamide (Fig. 5B). To ensure that
there were no androgens present in the cell culture media, LNCap
cells were incubated in charcoal-stripped serum for 48 h. The
basal level of ST3Gal I was not significantly different between the
LNCap cells cultured with 10% FBS and charcoal-stripped serum
(Fig. 5C). Then, the LNCap cells were treated with 100 nM
testosterone, and the time-course of the changes following
testosterone treatment was evaluated. The expression of ST3Gal
I increased 72 h after testosterone treatment and remained
elevated for more than 120 h in LNCap cells (Fig. 5C). In PC3
and PNT2 cells, no significant increase in the expression of
ST3Gal I was detected after testosterone treatment (Figure S5).
Next, we examined whether the regulation of ST3Gal I was
epigenetic in LNCap cells, as was the case for ST3Gal II. The
LNCap cells were treated with 5-azadC and incubated for 120 h
(Fig. 5D). The quantitative real-time PCR analyses showed that
the expression of ST3Gal I was up-regulated by 5-azadC
treatment. Next, LNCap cells were treated with TSA, and
incubated for 48 h (Fig. 5E). The quantitative real-time PCR
analyses showed that the expression of ST3Gal I was up-
regulated by TSA treatment. Thus, the regulation of ST3Gal I,
like the regulation of ST3Gal II, may be epigenetic and
androgen-dependent in LNCap cells. It was previously reported
that the p1 promoter of the human ST3Gal I gene is necessary
for the active transcription of the gene [31]. The ST3Gal I
promoter sequences are publically available, and, like ST3Gal II,
we identified a CpG island in the ST3Gal I p1 promoter using
the Methyl Primer Express Software program, version 1.0
(Applied Biosystems, Foster City, CA) (Figure S6A). The
methylation at the CpG island in the ST3Gal I promoter was
not detected in LNCap cells or in PC3 or DU145 cells by the
MSP analysis (Figure S6B), thus suggesting that the methylation
of a genome region other than the CpG island may affect the
expression of ST3Gal I in LNCap cells. Thus, the methylation
status of the CpG islands which affect the gene expression levels
are different between ST3Gal I and II.
RelB is required for androgen-dependent regulation of
ST3Gal I and II in LNCap cells
We next examined whether RelB was required for the
testosterone-mediated induction of ST3Gal I and II. LNCap cells
Figure 2. Androgen-dependent regulation of ST3Gal II in LNCap cells. (A) LNCap, PC3, and PNT2 cells were treated with or without
testosterone (0–1000 nM) for 120 h, by refeeding with fresh medium with or without testosterone at 72 h. The quantitative real-time PCR analyses of
ST3Gal II mRNA were performed, and the expression levels are reported as the means 6 S.E. (n=3) of the fold difference in mRNA after normalizing
the values to the expression level of untreated cells. **P,0.001. (B) LNCap cells were treated with or without testosterone (0–100 nM) and
simultaneously with or without 10 mM bicalutamide for 120 h, by refeeding with fresh medium with or without testosterone and/or bicalutamide at
72 h. The quantitative real-time PCR analyses for ST3Gal II were performed, and the expression levels are reported as the means 6 S.E. (n=3) of the
fold difference in mRNA after normalizing the values to the expression level of untreated cells. **P,0.001. (C) LNCap cells were incubated in charcoal-
stripped serum (CSS) for 48 h and then treated with 100 nM testosterone for the indicated times. The quantitative real-time PCR analyses for ST3Gal II
were performed, and the expression levels are reported as the means 6 S.E. (n=3) of the fold difference in mRNA after normalizing the values to the
expression level of untreated cells. *P,0.05, **P,0.001.
doi:10.1371/journal.pone.0031234.g002
Figure 3. Epigenetic regulation of ST3Gal II in LNCap cells. (A) LNCap cells were treated with 5-aza-29-deoxycytidine (5-azadC) (0–50 mM) for
120 h, by refeeding with fresh medium with or without 5-azadC at 72 h. The quantitative real-time PCR analyses for ST3Gal II were performed, and
the expression levels are reported as the means 6 S.E. (n=3) of the fold difference in mRNA after normalizing the values to the expression level of
untreated cells. *P,0.05. (B) LNCap cells were treated with 5 mM trichostatin A (TSA) for 48 h. The quantitative real-time PCR analyses for ST3Gal II
were performed, and the expression levels are reported as the means 6 S.E. (n=3) of the fold difference in mRNA after normalizing the values to the
expression level of untreated cells. *P,0.05.
doi:10.1371/journal.pone.0031234.g003
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31234Figure 4. Control of DNA methylation at the CpG island in the ST3Gal II promoter in prostate cancer cells. (A) The CpG island in the
ST3Gal II p1 promoter and the location of the MSP primers. The vertical bars represent CpG sites and TSS represents the transcriptional start site. (B–
D) The MSP analyses of the CpG island of ST3Gal II. DNA was isolated from LNCap cells treated with 5-azadC (0–50 mM) for 120 h (B), castration-
resistant prostate cancer cell lines (PC3 and DU145) or LNCap cells treated with or without 100 nM testosterone for 120 h (C) or LNCap cells treated
with or without 100 nM testosterone simultaneously with or without 10 mM bicalutamide for 120 h (D). Then, the DNA was treated with sodium
bisulfite, and finally amplified with primers specific for the unmethylated (USP) or the methylated (MSP) form of the CpG island in the ST3Gal II
promoter (M, methylated control; UA, unmethylated control A; UB, unmethylated control B). The MSP analyses were repeated 3 times with the same
results, and a representative image is shown in the figures.
doi:10.1371/journal.pone.0031234.g004
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31234Figure 5. Androgen-dependent and epigenetic regulation of ST3Gal I in LNCap cells. (A) LNCap cells were treated with or without
testosterone (0–1000 nM) for 120 h, by refeeding with fresh medium with or without testosterone at 72 h. The quantitative real-time PCR analyses for
ST3Gal I were performed, and the expression levels are reported as the means 6 S.E. (n=3) of the fold difference in mRNA after normalizing the
values to the expression level of untreated cells. **P,0.001. (B) LNCap cells were treated with or without testosterone (0–100 nM) and simultaneously
with or without 10 mM bicalutamide for 120 h, by refeeding with fresh medium with or without testosterone and/or bicalutamide at 72 h. The
quantitative real-time PCR analyses for ST3Gal I were performed, and the expression levels are reported as the means 6 S.E. (n=3) of the fold
difference in mRNA after normalizing the values to the expression level of untreated cells. **P,0.001. (C) LNCap cells were incubated in charcoal-
stripped serum (CSS) for 48 h and then treated with 100 nM testosterone for the indicated times. The quantitative real-time PCR analyses for ST3Gal I
were performed, and the expression levels are reported as the means 6 S.E. (n=3) of the fold difference in mRNA after normalizing the values to the
expression level of untreated cells. *P,0.05, **P,0.001. (D) LNCap cells were treated with 5-aza-29-deoxycytidine (5-azadC) (0–50 mM) for 120 h, by
refeeding with fresh medium with or without 5-azadC at 72 h. The quantitative real-time PCR analyses for ST3Gal I were performed, and the
expression levels are reported as the means 6 S.E. (n=3) of the fold difference in mRNA after normalizing the values to the expression level of
untreated cells. *P,0.05. (E) LNCap cells were treated with 5 mM trichostatin A (TSA) for 48 h. The quantitative real-time PCR analyses for ST3Gal I
were performed, and the expression levels are reported as the means 6 S.E. (n=3) of the fold difference in mRNA after normalizing the values to the
expression level of untreated cells. **P,0.001.
doi:10.1371/journal.pone.0031234.g005
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incubated for 120 h. The efficacy of RNAi was assessed by the
quantitative real-time PCR analyses (Figure S7). Next, LNCap
cells were transfected with either scrambled RNA or RelB siRNA
and incubated for 120 h with or without testosterone (Fig. 6). The
efficacy of the RelB RNAi was confirmed at the protein level by a
Western blot analysis. The levels of RelB protein were not greatly
modulated by testosterone treatment (Fig. 6A). The quantitative
real-time PCR analyses showed that, without testosterone, RelB
siRNA suppressed the expression of ST3Gal I, while no effect was
seen on the silenced ST3Gal II. However, the induction of both
ST3Gal I and II after testosterone treatment was inhibited by
RelB siRNA in the LNCap cells (Fig. 6B). Thus, RelB was
required for the androgen-dependent regulation of ST3Gal I and
II in LNCap cells.
Discussion
Gangliosides have been widely investigated because of their
relationship with cancer progression [3]. GD1a also appears to be
related to cancer cell proliferation and metastasis [11–15]. As
demonstrated in this study, GD1a was produced in abundance in
cancerous tissue samples from human patients with hormone-
sensitive prostate cancers as well as those with castration-resistant
prostate cancers. However, little is known about the regulation of
GD1a production. To address this lack of information, we have
been focusing on the transcription of the ST3Gal II gene, which is
required for the synthesis of GD1a. We previously reported that
ST3Gal II was up-regulated in human castration-resistant prostate
cancer cells and that the expression of ST3Gal II is regulated by
NF-kB, mainly by RelB [20]. Furthermore, a recent report
Figure 6. RelB is required for the androgen-dependent regulation of ST3Gal I and II in LNCap cells. (A) LNCap cells were transfected with
either scrambled RNA or RelB siRNA and incubated for 120 h with or without 100 nM testosterone. Protein extracts were prepared using RIPA lysis
buffer, and the RelB expression level of each sample was analyzed by a Western blot analysis. The expression relative to b-actin is shown in each lane
after normalizing the values to the expression level of the scrambled RNA–transfected and testosterone-untreated cells. (B) LNCap cells were
transfected with the either scrambled RNA or RelB siRNA and incubated for 120 h with or without 100 nM testosterone. The quantitative real-time
PCR analyses for ST3Gal I and II were performed, and the expression levels are reported as the means 6 S.E. (n=3) of the fold difference in mRNA
after normalizing the values to the expression level of the scrambled RNA–transfected and testosterone-untreated cells. *P,0.05, **P,0.001.
doi:10.1371/journal.pone.0031234.g006
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patients with high Gleason scores [32]. As demonstrated in this
study, the expression of ST3Gal II was constitutively activated and
androgen-independent in castration-resistant prostate cancer cells
(Fig. 2, Figure S2) because the CpG island in the ST3Gal II
promoter was hypomethylated (Fig. 4). However, in androgen-
depleted LNCap cells, a hormone-sensitive prostate cancer cell
line, ST3Gal II was not up-regulated in spite of the activation of
RelB.
We herein demonstrated that the expression of the ST3Gal II
required for the production of GD1a was epigenetically silenced
under androgen-depleted conditions and was up-regulated by
androgen-treatment in hormone-sensitive prostate cancer cells.
The CpG island of the ST3Gal II promoter was hypermethylated
under androgen-depleted conditions and was demethylated by
androgen treatment in hormone-sensitive prostate cancer cells
(Fig. 4). The presence of the androgen may promote a chromatin
environment where RelB can activate the transcription of
ST3Gal II in hormone-sensitive prostate cancer cells. Thus, in
hormone-sensitive prostate cancers, the production of GD1a may
be regulated by androgen, which can modulate the methylation
state of the CpG sites in the promoter region of a sialyltransferase
gene.
Although effects of androgen on NF-kB activity have been
reported, the topic remains controversial. One report showed that
androgen treatment repressed the NF-kB activity through
maintenance of the IkBa protein levels [33], but another report
showed that the NF-kB DNA binding activity increased after
androgen treatment [34]. In the present manuscript, the NF-kB
activity was not significantly different between the testosterone-
treated LNCap cells compared to the cells cultured without
testosterone (Figure S1). The two routes in NF-kB signaling are the
canonical pathway, which involves the complex formed between
RelA and p50, and the non-canonical pathway, in which the
complex formed between RelB and p52 is involved [35]. The
different subunits of NF-kB may be differently regulated by
androgens. Although the levels of nuclear RelA and p52 were not
elevated after androgen treatment in a previous report [34], it is
still unknown whether androgens can modulate the level of RelB.
In the present study, we showed that the levels of RelB protein
were not greatly modulated by androgens in the cell lines
examined (Fig. 6).
Although GD1a is synthesized from GM1 mainly by ST3Gal
I I ,S T 3 G a lIm a ya l s oc o n t r i b u t et ot h es y n t h e s i so fG D 1 a
[6,21–24]. We found that the expression of ST3Gal I was up-
regulated by 5-azadC treatment in LNCap cells, indicating that
the expression of ST3Gal I may be regulated by DNA
methylation, as is the case for ST3Gal II. However, methylation
at the CpG island in the ST3Gal I promoter was not detected in
LNCap cells by a MSP analysis. This suggests that the
methylation of a genome region other than the CpG island
may affect the expression of ST3Gal I. Thus, the methylation
status of CpG islands which af f e c tt h eg e n ee x p r e s s i o na r e
different between ST3Gal I and II. As previously reported [20],
in LNCap cells, ST3Gal I was expressed, while ST3Gal II
expression was silenced. The differences in the methylation of
the CpG island between ST3Gal I and II may result in the
differences in the expression of these two genes in LNCap cells.
Based on publically available data and previous studies [36,37],
we identified that ST3Gal II has one highly probable androgen
receptor recruitment site 239.5 kb of the transcription start site
of the ST3Gal II p1 promoter, and that the ST3Gal I has two
highly probable androgen receptor recruitment sites 213.9 kb
and 242.6 kb of the transcription start site of the ST3Gal I p1
promoter. Thus, as there are differences in the methylation
status of CpG islands, the regulation of promoter methylation
by the androgen receptor might also be different between
ST3Gal I and II.
The progression of many cancers is epigenetically regulated.
DNA demethylation changes have been reported to occur later
in prostate carcinogenesis [38,39]. We first demonstrated that
the androgen-dependent activation of transcription was induced
by demethylation of CpG promoter region in ST3Gal II.
Recently, several reports have shown that DNA methylation can
be controlled by hormone receptors. For example, the estrogen
receptor directly modifies the methylation status of the pS2 gene
[40,41], and the glucocorticoid receptor could also modify the
DNA methylation status [42]. Another report showed that DNA
methylation/demethylation was hormonally altered to control
the transcription of the cytochrome p450 27B1 gene, and that
the 5-methyl-CpG binding domain family (MBD) protein
activated by hormonal stimulation seemed to complete the
DNA demethylation in the MBD-bound promoter [43]. In the
present study, we demonstrated that demethylation of the
ST3Gal II promoter was induced by androgen treatment in
hormone-sensitive prostate cancer cells. Although the mecha-
nism is currently unclear, the MBD protein may be involved in
this type of androgen-induced DNA demethylation. Further
research is needed to elucidate the mechanism underlying the
hormonal control of the DNA methylation/demethylation of the
ST3Gal II promoter.
Androgen plays a pivotal role in the development, growth, and
progression of prostate cancers [25]. Although we have herein
shown the androgen-dependent activation of ST3Gal II by the
demethylation of CpG promoter region, other genes may also be
epigenetically regulated by androgen treatment in hormone-
sensitive prostate cancer cells. Although we focused on DNA
methylation at the CpG island in the ST3Gal promoter in the
current manuscript, it is known that DNA methylation is linked to
histone deacetylation [44,45]. Therefore, in future studies, we plan
to elucidate the mechanism underlying the regulation on histone
modification by androgen, in addition to the effects on DNA
methylation.
GD1a should be focused also from the view of cancer therapy.
Several gene therapy approaches for the treatment of prostate
cancer have been clinically tested [46]. Oncolytic viruses have
been developed to selectively augment the anti-tumor effects, and
some viruses, such as adenovirus and the herpes simplex virus, are
used to combat prostate cancers [47,48]. Recently, we reported
that inactivated Sendai virus particles (HVJ-E) selectively induced
apoptosis in human castration-resistant prostate cancer cells by
retinoic acid-inducible gene-I (RIG-I)–mediated gene expression
and the induction of anti-tumor immunities [17]. A ganglioside,
GD1a, which is enriched in human castration-resistant prostate
cancer cells [17–20] is one of the receptors for the Sendai virus
[16]; therefore, HVJ-E is expected to be a novel therapeutic tool
for prostate cancers. However, HVJ-E did not induce apoptosis in
LNCap cells, a human hormone-sensitive prostate cancer cell line,
because these cells did not express a viral receptor ganglioside,
such as GD1a [17], on their cell surface. The present study showed
that GD1a was produced in clinical samples of hormone-sensitive
prostate cancers and of castration-resistant prostate cancers. We
are currently analyzing the mechanism underlying the cancer-
selective apoptosis induced by HVJ-E, and our preliminary data
suggest that both castration-resistant and hormone-sensitive
prostate cancers may be treated by HVJ-E. Thus, this study will
also be important to determine the indications for treating prostate
cancer patients with HVJ-E.
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Figure S1 NF-kB activity after testosterone treatment in
LNCap cells. LNCap cells were transfected with a NF-kB
luciferase reporter construct and incubated for 120 h with or
without 100 nM testosterone. The luciferase activity was mea-
sured, and the results are shown as the means 6 S.E. (n=3).
(EPS)
Figure S2 Androgen-independent regulation of ST3Gal
II in PC3 cells. PC3 cells were incubated in charcoal-stripped
serum (CSS) for 48 h and then treatedwith100 nM testosterone for
the indicated times. The quantitative real-time PCR analyses for
ST3GalIIwereperformed,andtheexpressionlevelsarereportedas
the means 6 S.E. (n=3) of the fold difference in mRNA after
normalizing the values to the expression level of untreated cells.
(EPS)
Figure S3 Testosterone does not induce global DNA
demethylation in LNCap cells. (A) The results of the
differential restriction analysis. The genomic DNA isolated from
untreated LNCap cells or LNCap cells treated with 100 nM
testosterone for 120 h was digested using MspIo rHpaII for 16 h at
37uC. The digested DNA was analyzed in 2% agarose gels stained
with ethidium bromide. (B) The results of the MSP analysis of
GSTP1.Thegenomic DNAisolatedfrom untreated LNCap cellsor
LNCap cells treated with 100 nM testosterone for 120 h was
amplified with primers specific for the unmethylated (USP) or the
methylated (MSP) GSTP1 promoter after treatment with sodium
bisulfite (M, methylated control; UA, unmethylated control A; UB,
unmethylated control B). The MSP analyses were repeated 3 times
with the same result and a representative image shown in the figure.
(EPS)
Figure S4 Androgen-independent regulation of ST3Gal
VI in LNCap cells. LNCap cells were treated with testosterone
(0–1000 nM) for 120 h, by refeeding with fresh medium with or
without testosterone at 72 h. The quantitative real-time PCR
analyses for ST3Gal VI were performed, and the expression levels
are reported as the means 6 S.E. (n=3) of the fold difference in
mRNA after normalizing the values to the expression level of
untreated cells.
(EPS)
Figure S5 Androgen-independent regulation of ST3Gal I
in PC3 and PNT2 cells. PC3 and PNT2 cells were treated with
testosterone (0–1000 nM) for 120 h, by refeeding with fresh
medium with or without testosterone at 72 h. The quantitative
real-time PCR analyses for ST3Gal I were performed, and the
expression levels are reported as the means 6 S.E. (n=3) of the
fold difference in mRNA after normalizing the values to the
expression level of untreated cells.
(EPS)
Figure S6 Control of DNA methylation at the CpG
island in the ST3Gal I promoter in prostate cancer cells.
(A) The CpG island in the ST3Gal I p1 promoter and the location
of the MSP primers. The vertical bars represent CpG sites and
TSS represents the transcriptional start site. (B) The MSP analysis
of ST3Gal I. DNA was isolated from castration-resistant prostate
cancer cell lines (PC3 and DU145) or LNCap cells which were
treated with or without 100 nM testosterone for 120 h, and then
treated with sodium bisulfite, and was finally amplified with
primers specific for the unmethylated (USP) or the methylated
(MSP) form of the CpG island in the ST3Gal I promoter (M,
methylated control; UA, unmethylated control A; UB, unmethy-
lated control B). The MSP analyses were repeated 3 times with the
same result and a representative image shown in the figure.
(EPS)
Figure S7 The efficacy of RelB RNAi as assessed by the
quantitative real-time PCR analyses. LNCap cells were
transfected with either scrambled RNA or RelB siRNA and
incubated for 120 h. The total RNA from LNCap cells transfected
with either the scrambled RNA or RelB siRNA were subjected to
the quantitative real-time PCR analyses, and the results are shown
as the means 6 S.E. (n=3). **P,0.001.
(EPS)
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